Palvella Therapeutics Cash Flow Statement
NASDAQ: PVLAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
138.77+7.43 (+5.66%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Palvella Therapeutics free cash flow
In fiscal 2025, Palvella Therapeutics generated -$25.0 million of operating cash flow. That left free cash flow of -$25.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Palvella Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -41.72M | -17.43M | 18.69M | -33.28M | -45.74M | -37.23M | -25.47M | -26.75M | -17.65M | -22.80M |
| Net Income growth (YoY) | — | -193.27% | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | — | — | 1.90M | 2.77M | 2.46M | 2.10M | 600.00K | 570.00K | 369.00K | 361.00K |
| Stock-Based Compensation | 6.40M | 830.00K | 603.00K | 4.40M | 5.21M | 5.09M | 5.37M | 4.94M | 3.05M | 1.91M |
| Change in Working Capital | 3.01M | 735.00K | -36.63M | -8.19M | 21.64M | -14.01M | -32.00M | 18.64M | 61.48M | 4.03M |
| Operating Cash Flow | -25.01M | -10.84M | -13.70M | -59.93M | -7.66M | -45.90M | -52.47M | -1.07M | 49.75M | -14.39M |
| Capital Expenditures | — | — | -171.00K | -1.04M | -949.00K | -2.73M | -2.46M | -1.70M | -1.95M | -560.00K |
| Investing Cash Flow | — | — | 12.00M | -21.24M | -949.00K | 39.21M | 9.84M | -8.88M | -45.88M | -560.00K |
| Financing Cash Flow | -660.00K | 87.09M | 5.00M | 7.21M | 59.13M | 10.12M | 32.17M | 48.51M | 4.09M | 15.22M |
| Net Change in Cash | -25.62M | 76.25M | -8.70M | -79.13M | 47.33M | 8.18M | -12.61M | 36.99M | 8.52M | 6.00K |
| Free Cash Flow | -25.01M | -10.84M | -13.87M | -60.97M | -8.61M | -48.62M | -54.93M | -2.76M | 47.80M | -14.95M |
This table shows 10 annual periods of Palvella Therapeutics's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow PVLA's reporting calendar. What is a cash flow statement?